Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy

Why, When, and How Should Pharmacogenetics Be Applied in Clinical Studies?: Current and Future Approaches to Study Designs

(2011) J C Stingl (formerly Kirchheiner) et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer

(2010) Motofumi Tanaka et al.   CANCER

MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

(2010) Elisa Giovannetti et al.   CANCER RESEARCH

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study

(2010) Giuseppe Colucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

(2010) Shu-zhen Wei et al.   MEDICAL ONCOLOGY

Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib

(2010) E. Giovannetti et al.   MOLECULAR CANCER THERAPEUTICS

Advanced pancreatic carcinoma: current treatment and future challenges

(2010) Anastasios Stathis et al.   Nature Reviews Clinical Oncology

Pharmacogenomics in non-small-cell lung cancer chemotherapy

(2009) Romano Danesi et al.   ADVANCED DRUG DELIVERY REVIEWS

Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes and Pancreatic Cancer Survival and Drug Toxicity

(2009) T. Okazaki et al.   CLINICAL CANCER RESEARCH

Significant Associations of Mismatch Repair Gene Polymorphisms With Clinical Outcome of Pancreatic Cancer

(2009) Xiaoqun Dong et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Studies of Gemcitabine and Cisplatin in Heavily and Minimally Pretreated Metastatic Breast Cancer

(2009) Helen K. Chew et al.   JOURNAL OF CLINICAL ONCOLOGY

Polymorphisms of p16, p27, p73, and MDM2 Modulate Response and Survival of Pancreatic Cancer Patients Treated with Preoperative Chemoradiation

(2008) Jinyun Chen et al.   ANNALS OF SURGICAL ONCOLOGY

Detecting Pathway-Based Gene-Gene and Gene-Environment Interactions in Pancreatic Cancer

(2008) E. J. Duell et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Polymorphisms in DNA Repair Genes, Smoking, and Pancreatic Adenocarcinoma Risk

(2008) R. R. McWilliams et al.   CANCER RESEARCH

Single-Nucleotide Polymorphisms of DNA Damage Response Genes Are Associated with Overall Survival in Patients with Pancreatic Cancer

(2008) T. Okazaki et al.   CLINICAL CANCER RESEARCH

Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

(2008) C. Tibaldi et al.   CLINICAL CANCER RESEARCH

Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players

(2008) M. P. Kim et al.   CLINICAL CANCER RESEARCH

Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel

(2008) T. M. Sissung et al.   MOLECULAR CANCER THERAPEUTICS